Clinical Trials Logo

Mitral Valve Insufficiency clinical trials

View clinical trials related to Mitral Valve Insufficiency.

Filter by:

NCT ID: NCT05475561 Completed - Clinical trials for Mitral Regurgitation

Comparison of Erector Spinae Block and Pecto-Intercostal Facial Block For Enhanced Recovery in Adult Cardiac Surgery

Start date: May 25, 2022
Phase: Phase 2
Study type: Interventional

The current study is designed to compare the perioperative analgesic efficacy of Erector spinae plane block (ESPB) and Pecto-intercostal-fascial plane block (PIFB) in adults undergoing cardiac surgery via median sternotomy. The primary outcome measure will be the analgesic effectiveness of both blocks in median sternotomy pain, while the secondary outcome measures will be time to extubation, and length of intensive care unit stay.

NCT ID: NCT05469165 Recruiting - Clinical trials for Ischemic Mitral Regurgitation

Serotonin Receptor Blockers in Ischemic Mitral Regurgitation

CYPRO-MR
Start date: June 20, 2023
Phase: Phase 2
Study type: Interventional

This study is intended to investigate the effect of cyproheptadine (a 5HT2B receptor blocker) on mitral regurgitation severity.

NCT ID: NCT05455489 Recruiting - Clinical trials for Mitral Valve Regurgitation

GISE Registry of Transcatheter Treatment of Mitral Valve Regurgitation With the MitraClip G4

Start date: January 25, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of the GISE study is to confirm the MitraClip safety and improve the device effectiveness in a selected all comers ("more-comers") population with symptomatic severe mitral regurgitation undergoing/undergone Transcatheter Edge-to-Edge Repair (TEER) with MitraClip G4.

NCT ID: NCT05425628 Not yet recruiting - Clinical trials for Cardiovascular Diseases

European FIH Study - NeoChord Transcatheter Mitral Repair System for Symptomatic Mitral Regurgitation

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Safety and performance evaluation of the NeoChord Transcatheter Mitral Repair System in patients with degenerative mitral valve regurgitation.

NCT ID: NCT05417945 Not yet recruiting - Clinical trials for Mitral Valve Regurgitation

A Prospective, Multicenter Study to Evaluate the JensClip Transcatheter Valve Repair System

Start date: June 2022
Phase: N/A
Study type: Interventional

The clinical trial study is designed as a prospective, multicenter, single-group target value clinical study to evaluate the safety and efficacy of the clinical investigational product and to evaluate its performance using the above clinical trial primary endpoint and secondary endpoint indicators.

NCT ID: NCT05403840 Not yet recruiting - Clinical trials for Mitral Regurgitation

Haemodynamics of Mitral Regurgitation Reduction

STRESS-MR
Start date: June 6, 2022
Phase:
Study type: Observational

There is uncertainty in terms of the superiority of conventional valve surgery or percutaneous transcatheter intervention for the treatment of severe mitral regurgitation (MR) in high risk patients. The post procedural haemodynamics of the different treatment options in those at high surgical risk is poorly understood. This study seeks to characterise the physiological changes and functional outcomes of patients undergoing either surgery or transcatheter intervention.

NCT ID: NCT05391802 Not yet recruiting - Clinical trials for Mitral Regurgitation

The Multicenter Clinical Trial of a Novel TEER Decive (V-CLASP Trial)

Start date: June 30, 2022
Phase: N/A
Study type: Interventional

This is a single-group, prospective, multicenter clinical research using the single-arm objective performance criteria. Patients with moderate to severe mitral regurgitation and a high surgical risk will be treated with ValveClasp®, a novel transcatheter mitral edge-to-edge repair system. The subjects will be followed postoperatively, before discharge, for one month, six months, and twelve months. immediately following operation, before discharge, and at 1, 6, and 12 months after surgery, with follow-up at 2, 3, 4, and 5 years. The follow-ups began immediately before discharge and continued for one month, six months, and twelve months after surgery, with extensions to two, three, four, and five years.

NCT ID: NCT05374733 Recruiting - Clinical trials for Coronary Artery Disease

Coronary Physiology Peri-Transcatheter Left-sided Valvular Interventions

POTUS
Start date: March 22, 2021
Phase: N/A
Study type: Interventional

Prospective, single-arm, observational study with invasive coronary physiology measurements before and after transcatheter left-sided valvular intervention.

NCT ID: NCT05345730 Recruiting - Surgery Clinical Trials

The Role of Left Atrial Fibrosis in Mitral Valve Repair Surgery (ALIVE Trial)

ALIVE
Start date: February 2, 2022
Phase:
Study type: Observational

Rationale: Patients with mitral valve insufficiency suffer from left atrial remodeling. Atrial fibrosis is part of this remodeling process. The presence of atrial fibrosis is associated with adverse events. Currently, mitral valve repair surgery is the ultimate treatment for severe primary mitral valve insufficiency. The main indications and timing for surgery are severe mitral valve insufficiency with symptoms or left ventricular dysfunction. However, the role of atrial fibrosis in this process remains undetermined despite its well-recognized clinical implications. Characterization of atrial fibrosis patterns in mitral valve insufficiency patients might be potentially valuable for the indication and timing of mitral valve repair surgery in order to improve clinical outcomes. To date, however, mitral valve insufficiency patients suffering from left atrial remodeling have hardly been studied using these new imaging techniques. Therefore, the investigators intend to combine advanced cardiac MRI and post-processing techniques prior to and after mitral valve repair surgery to gain more insight in the clinical implications of atrial fibrosis in this patient population. It is hypothesized that the atrial fibrosis surface area paradoxically will increase after mitral valve surgery because of global shrinkage of the left atrium caused by the reversed remodeling process. As a consequence, more frequently atrial fibrosis related events including (paroxysmal) atrial fibrillation, may be observed in these patients. Objective: To assess the effects of (reduced) volume overload on the left atrial wall texture (presence, amount and location of atrial fibrosis) and associated geometry and function in patients with mitral valve insufficiency, prior to and after mitral valve repair surgery. Study design: Single center pilot study. Study population: The research population consists of mitral valve insufficiency patients scheduled for elective surgical mitral valve repair (N=20) according to the current European guideline criteria.

NCT ID: NCT05332782 Recruiting - Clinical trials for Mitral Regurgitation

Outcomes of Patients tReated wIth Mitral Transcatheter Edge-to-edge Repair for Primary Mitral Regurgitation Registry

PRIME-MR
Start date: March 1, 2022
Phase:
Study type: Observational

This multinational, non-interventional, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent mitral valve transcatheter edge-to-edge repair (M-TEER) for primary mitral regurgitation (PMR).